iGlarLixi: a new once-daily fixed-ratio combination of basal insulin glargine and lixisenatide for the management of type 2 diabetes
Clinical Pearl: Ideal Candidates for Combination Therapy Patients that will greatly benefit from L-carnitine adjunctive therapy: Report persistent fatigue despite adequate weight loss on GLP-1 therapy alone Demonstrate signs of muscle loss or declining lean body mass during treatment Have plateaued in their weight loss despite medication optimization Present with metabolic syndrome features beyond elevated BMI (dyslipidemia, insulin resistance) Engage in regular physical activity and seek enhanced athletic performance alongside weight management Monitoring Parameters Regular assessment should include: Weight and body composition measurements every 4-6 weeks Lipid panel and HbA1c at 3-month intervals Liver function tests at baseline and 6 months (L-carnitine may affect hepatic fat metabolism) Patient-reported outcomes: energy levels, GI tolerability, exercise capacity Prescribing Patterns & Updates Growing Interest in Combination Metabolic Therapies Clinical practice patterns indicate increasing adoption of adjunctive therapies alongside GLP-1 medications
I'd love to dive into this culinary medicine chest, with you
Sneakers that lace up
It is a good fit for you if: You are 18 to 75 You have a body mass index (BMI) of 30 to 39 or 27-29 with qualifying weight-related health conditions You do not have coverage for weight loss medications You do not have health conditions that restrict your ability to safely take weight loss medications and participate in the program MWMRx is only available to those who do not currently have coverage for weight loss medications since it is a fee for service program
A meta-analysis revealed that a 2.4 mg dose of semaglutide led to a reduction of 12.4 kg of body weight, while doses of 3.0 mg of liraglutide, 1.0 mg of semaglutide, and 1.8 mg of liraglutide led to reductions in body weight of 5.2 kg, 3.7 kg, and 1.8 kg, respectively
